Yoshiyasu Kono

20PUBLICATIONS
23CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsImmunogenetics (incl. genetic immunology)Cancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 28, 2026
Residual Platinum-Induced Neuropathy and the Feasibility of Second-Line Paclitaxel-Ramucirumab Therapy in Advanced Gastric Cancer: Prospective Multicenter Evidence from Japan.

|Jan 27, 2026
HER2 reassessment triggered by comprehensive genomic profiling reveals a therapeutic opportunity in refractory gastric cancer: a case report.

Takaaki Iwado, Yoshiyasu Kono, Motoyuki Otsuka

|Aug 28, 2025
Prognostic Impact of Gastrointestinal Immune-Related Adverse Events Depends on Nutritional Status in Cancer Patients Treated with Immune Checkpoint Inhibitors.

Shoichiro Hirata, Yoshiyasu Kono, Emi Tanaka

|Jun 13, 2025
Distinct age-related effects of homologous recombination deficiency on genomic profiling and treatment efficacy in gastric cancer.

Yoshie Maki, Yoshiyasu Kono, Toshiki Ozato

|Apr 18, 2025
Genomic Differences and Distinct TP53 Mutation Site-Linked Chemosensitivity in Early- and Late-Onset Gastric Cancer.

Tomohiro Kamio, Yoshiyasu Kono, Kensuke Hirosuna

|Mar 11, 2025
Correction: Clinical Significance of Prior Ramucirumab Use on the Effectiveness of Nivolumab as the Third-Line Regimen in Gastric Cancer: A Multicenter Retrospective Study.

Yuka Obayashi, Shoichiro Hirata, Yoshiyasu Kono

Pageof 4

Frequent Collaborators

4 joint publications

Masaya Iwamuro

2 joint publications

Shotaro Okanoue

2 joint publications

Kenta Hamada

2 joint publications

Hiromitsu Kanzaki